Foresite Capital Management Iii, LLC Replimune Group, Inc. Transaction History

Foresite Capital Management Iii, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$8.9 - $19.08 $2.79 Million - $5.99 Million	-313,922 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$11.61 - $17.21 $2.97 Million - $4.4 Million	-255,740 Reduced 44.89%	313,922 $4.51 Million
Q3 2019 Nov 13, 2019	SELL	$10.01 - $16.87 $2.1 Million - $3.54 Million	-209,994 Reduced 26.93%	569,662 $7.92 Million
Q2 2019 Aug 13, 2019	BUY	$12.51 - $17.28 $375,325 - $518,434	30,002 Added 4.0%	779,656 $11.4 Million
Q1 2019 May 14, 2019	SELL	$10.26 - $16.24 $307,820 - $487,232	-30,002 Reduced 3.85%	749,654 $11.9 Million
Q3 2018 Nov 13, 2018	BUY	$14.99 - $22.14 $11.7 Million - $17.3 Million	779,656 New	779,656 $12.6 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.